MALT1 and B-cell chronic lymphocytic leukemia: Safimaltib was recently developed as a specific MALT1 paracaspase inhibitor (40), and it is currently under early clinical investigation in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia (ClinicalTrials.gov NCT03900598).